文献速递消化道肿瘤放疗姑息放疗与转移瘤

化疗免疫联合放疗可改善复发或转移性食管癌生存

Survival Benefit of Combined Chemoimmunotherapy and Radiation Therapy in Patients with Recurrent or Metastatic Esophageal Cancer.
PubMed 文献 · Adv Radiat Oncol · 2025-08-22

这项回顾性队列研究纳入178例复发或转移性食管癌患者,经倾向评分匹配后128例分为化疗免疫组与化疗免疫联合放疗组。

要点

  • 两组均未发生治疗相关死亡,联合方案安全可耐受。

核心结论

  • 在化疗免疫治疗基础上加用放疗可显著改善复发或转移性食管癌患者的总生存和无进展生存,但需前瞻性试验验证。

研究设计与样本

  • 回顾性队列研究,分析2019年12月至2023年10月中国科学技术大学附属第一医院178例复发或转移性食管癌患者資料,按实际治疗方案分为化疗免疫组和化疗免疫联合放疗组,采用倾向评分匹配平衡基线特征。

主要发现

  • 匹配后128例纳入最终分析,联合放疗组与对照组各64例,中位随访11.26个月(95%CI 7.02-15.32)。
  • 联合方案安全可耐受,两组均无治疗相关死亡。

临床怎么用

  • 对接受化疗免疫治疗的复发或转移性食管癌患者,可考虑联合放疗以改善生存,具体适应证需结合前瞻性证据进一步明确。

局限性

  • 为单中心回顾性研究,样本量有限,结论需前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chemotherapy combined with immune checkpoint inhibitors (ICIs) has become the standard first-line treatment for recurrent or metastatic esophageal cancer, but its efficacy remains suboptimal. This study aimed to evaluate whether the addition of radiation therapy (RT) to ICIs can improve patients' survival. METHODS AND MATERIALS: This retrospective cohort study analyzed clinical data from 178 patients with recurrent or metastatic esophageal cancer who were treated at the First Affiliated Hospital of USTC between December 2019 and October 2023. Based on their actual treatment regimens, patients were stratified into 2 groups: the chemoimmunotherapy-alone group (ICIs group) and the chemoimmunotherapy combined with RT group (ICIs + RT group). To minimize selection bias, propensity score matching was used to balance baseline characteristics between the groups before comparative analysis. The primary endpoint was overall survival, and the secondary endpoints were progression-free survival and safety. RESULTS: After propensity score matching, 128 patients were selected for the final analysis, with 64 patients in the ICIs + RT group and 64 patients in the ICIs group. The median follow-up time was 11.26 months (95% CI, 7.02-15.32). The median overall survival was 23.71 months in the ICIs + RT group and 13.00 months in the ICIs group (hazard ratio, 0.53; 95% CI, 0.31-0.88; P = .013). The median progression-free survival was 10.43 months in the ICIs + RT group and 7.27 months in the ICIs group (hazard ratio, 0.61; 95% CI, 0.39-0.94; P = .024). Combination of chemoimmunotherapy and RT was safe and tolerable. No treatment-related deaths occurred in either group. CONCLUSIONS: Adding RT can significantly improve survival in patients with recurrent or metastatic esophageal cancer who are treated with chemoimmunotherapy, but further prospective trials are needed for validation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang X, Guo D, Li X, et al. Survival Benefit of Combined Chemoimmunotherapy and Radiation Therapy in Patients with Recurrent or Metastatic Esophageal Cancer. Adv Radiat Oncol. 2025. PMID: 41050919. doi:10.1016/j.adro.2025.101890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。